Repository of Phase Signals for Pulmonary Hypertension Algorithm Development

NCT ID: NCT04031989

Last Updated: 2024-03-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

2500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-04-15

Study Completion Date

2024-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed as a repository study to collect resting cardiac phase signals and subject meta data from eligible subjects using the Phase Signal Recorder (PSR) prior to Right Heart Cath (RHC). The repository data will be used for the purposes of research, development, optimization and testing of machine-learning algorithms developed by CorVista Health (formerly Analytics 4 Life).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Male and Female subjects will be uniquely and consecutively enrolled into one group to support populating a repository of phase signals. Resting phase signals will be collected in all patients who meet inclusion/exclusion criteria and have signed an informed consent form. This study consists of a screening visit, resting phase signal collection (study procedure), and right heart catheterization. In this study, resting phase signals will be acquired in subjects prior to Right Heart Catheterization.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Diseases Right Heart Failure Cardiac Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Repository study designed to collect signals using the CorVista Capture in subjects scheduled for Right Heart Catheterization
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Enrolled Subjects (PSR)

Patients who meet the study's entrance criteria and provide written informed consent, will undergo signal acquisition prior to their scheduled right heart catheterization (RHC) on the day of the procedure.

Group Type OTHER

CorVista Capture

Intervention Type DEVICE

The CorVista System is a medical device system that is being developed to collect phase signals from patients to support the development and testing of machine learned algorithms developed by CorVista Health. Data collected with the CorVista System during this study will not be used to guide treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CorVista Capture

The CorVista System is a medical device system that is being developed to collect phase signals from patients to support the development and testing of machine learned algorithms developed by CorVista Health. Data collected with the CorVista System during this study will not be used to guide treatment.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients ≥ 18 years old;
2. Scheduled to undergo right heart catheterization;
3. Ability to understand the requirements of the study and to provide written informed consent.
4. Normal Sinus Rhythm (SSR) at time of phase signal collection.

Exclusion Criteria

1. Prior heart valve replacement
2. Prior lung or heart transplant
3. Infiltrative myocardial disease (amyloid, sarcoid, right ventricular dysplasia);
4. Presence of cardiac implantable electronic device (CIED), including implantable cardioverter defibrillator (ICD), pacemaker (PM), implantable loop recorders and other monitors;
5. Implantable Neuro-stimulators;
6. Congenital Heart Disease;
7. Pregnant or breast feeding;
8. Currently taking any Type IA, IC or III antiarrhythmics;
9. Any history of amiodarone use;
10. Clinically significant chest deformity (e.g., pectus excavatum or pectus carinatum);
11. Breast implants;
12. Neuromuscular Disease if the condition results in tremor or muscle fasciculations.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Analytics For Life

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Horace R Gillins, BS CCRP

Role: STUDY_DIRECTOR

CorVista Health

William E Sanders, Jr, MD JD LLM MBA FHRS

Role: STUDY_DIRECTOR

CorVista Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UC-MHS (UCHealth Memorial)

Colorado Springs, Colorado, United States

Site Status

University of Colorado-MHS (UCHealth Memorial)

Colorado Springs, Colorado, United States

Site Status

WellStar Research Institute

Marietta, Georgia, United States

Site Status

Loyola University Chicago

Maywood, Illinois, United States

Site Status

Cardiology Associates Research, LLC

Tupelo, Mississippi, United States

Site Status

Bryan Heart

Lincoln, Nebraska, United States

Site Status

The Rochester General Hospital

Rochester, New York, United States

Site Status

Duke University

Durham, North Carolina, United States

Site Status

LeBauer Cardiovascular Research Foundation

Greensboro, North Carolina, United States

Site Status

New Hanover Regional Medical Center

Wilmington, North Carolina, United States

Site Status

Allegheny Health Network Research Institute

Natrona Heights, Pennsylvania, United States

Site Status

Allegheny Health Network Research Institute

Pittsburgh, Pennsylvania, United States

Site Status

AnMed Health

Anderson, South Carolina, United States

Site Status

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

Lexington Cardiology / Lexington Medical Heart and Vascular Center

Lexington, South Carolina, United States

Site Status

Austin Heart

Austin, Texas, United States

Site Status

Sentara Hospitals and Sentara Medical Group

Norfolk, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PHDEV-CIP-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.